Access cutting-edge eczema atopic dermatitis treatment through this phase 2/3 clinical trial at a research site in Irving. Study-provided care at no cost to qualified participants.
Quick Self-Assessment
See if you qualify for this Irving location
Preparing your pre-screening questions…
Access eczema atopic dermatitis specialists at no cost
This study follows strict safety protocols and ethical guidelines
All study-related eczema atopic dermatitis treatment provided free
Check if you qualify for this eczema atopic dermatitis clinical trial in Irving, TX
No-Cost Study Care
Local to Irving
Convenient for TX residents
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel
*Compensation varies by study. Confirm details with coordinator.
This is a Phase 2, randomized, double-blind, vehicle-controlled clinical study evaluating the efficacy and safety of GX-03 topical ointment in adult subjects with moderate to severe atopic dermatitis (eczema). The study plans to enroll up to 120 eligible patients with a target of at least 100 completing the study and an ability to expand enrollment up to 200 subjects based on a pre-specified interim assessment conducted by an Independent Data Monitoring Committee (IDMC). Subjects will be randomized in a 1:1 ratio to receive either GX-03 or vehicle control for 8 weeks. The study is designed to evaluate improvement in investigator-assessed disease severity, itch, and patient-reported eczema symptoms following topical treatment with GX-03 compared with vehicle control. Efficacy assessments include the Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD™), Eczema Area and Severity Index (EASI), Peak Pruritus Numeric Rating Scale (PP-NRS), and Patient-Oriented Eczema Measure (POEM). An interim assessment of conditional power for the primary efficacy endpoint will occur after the first 50 subjects complete the Week 8 visit or withdraw prematurely. Based on pre-specified criteria defined in the IDMC Charter, the IDMC may recommend continuation as planned, expansion of enrollment up to 200 subjects, or early curtailment of enrollment.
Sponsor: Turn Therapeutics
Yes, this clinical trial (NCT07355075) has an active research site in Irving, TX that is currently enrolling participants.
Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.
Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.
Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.
If you're searching for eczema atopic dermatitis treatment options in Irving, TX, this clinical trial (NCT07355075) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Irving research site is actively enrolling participants for this phase 2/3 clinical trial. You'll receive care from experienced eczema atopic dermatitis specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.
Looking for more options? Browse all eczema atopic dermatitis clinical trials near you to find additional studies recruiting in your area.
See all atopic dermatitis clinical trials recruiting in Irving — not just this study.
Browse Atopic Dermatitis Trials in Irving →